Abstract | PURPOSE: DESIGN: Observational case series. METHODS: Fifteen eyes of 13 patients (5 men, 8 women; mean age, 59 years; range, 54 to 70 years) treated with 1-mg intravitreal bevacizumab injections were included. The minimum follow-up after the first injection was 12 months. Eyes that had undergone previous treatments were excluded. The best-corrected visual acuity (BCVA) was measured. Optical coherence tomography and fluorescein angiography images were examined before and after treatment. RESULTS: The mean follow-up was 19 months (range, 12 to 24 months). The mean number of injections for primary CNV was 4.5 (range, 1 to 9). The mean preoperative BCVA (decimal equivalent) was 0.39 (range, 0.08 to 1.5) and 0.47 (range, 0.06 to 1.2) at the final visit (P = .355). The BCVA improved by 2 lines of logarithm of the minimum angle of resolution visual acuity at the final visit in 5 eyes (33%), was unchanged in 8 eyes (54%), and decreased in 2 eyes (13%). The final fluorescein angiography examination showed no leakage in 10 eyes (67%), minimal leakage in 2 eyes (13%), and persistent or recurrent leakage in 3 eyes (20%). Five eyes (33%) had a recurrence 4 to 7 months (mean, 5.1 months) after the last bevacizumab injection. New CNV lesions developed in different areas in 3 eyes (20%) 6 to 14 months after the last bevacizumab injection for primary CNV. CONCLUSIONS:
|
Authors | Miki Sawa, Fumi Gomi, Motokazu Tsujikawa, Hirokazu Sakaguchi, Yasuo Tano |
Journal | American journal of ophthalmology
(Am J Ophthalmol)
Vol. 148
Issue 4
Pg. 584-590.e2
(Oct 2009)
ISSN: 1879-1891 [Electronic] United States |
PMID | 19541288
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Aged
- Angiogenesis Inhibitors
(adverse effects, therapeutic use)
- Angioid Streaks
(complications)
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Choroidal Neovascularization
(drug therapy, etiology, physiopathology)
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Injections
- Male
- Middle Aged
- Retreatment
- Retrospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
- Vitreous Body
|